Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. trimmed its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 44.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,258,208 shares of the biopharmaceutical company's stock after selling 1,015,751 shares during the quarter. Victory Capital Management Inc. owned about 0.42% of Amicus Therapeutics worth $13,438,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Assenagon Asset Management S.A. acquired a new stake in shares of Amicus Therapeutics in the 2nd quarter valued at approximately $8,386,000. M&G Plc increased its stake in shares of Amicus Therapeutics by 12.4% in the 2nd quarter. M&G Plc now owns 748,451 shares of the biopharmaceutical company's stock valued at $7,485,000 after acquiring an additional 82,728 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its stake in shares of Amicus Therapeutics by 7.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 100,538 shares of the biopharmaceutical company's stock valued at $1,183,000 after acquiring an additional 7,304 shares in the last quarter. Fiera Capital Corp increased its stake in shares of Amicus Therapeutics by 1.1% in the 2nd quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company's stock valued at $52,382,000 after acquiring an additional 58,113 shares in the last quarter. Finally, Mutual of America Capital Management LLC increased its stake in shares of Amicus Therapeutics by 24.2% in the 2nd quarter. Mutual of America Capital Management LLC now owns 250,293 shares of the biopharmaceutical company's stock valued at $2,483,000 after acquiring an additional 48,802 shares in the last quarter.

Amicus Therapeutics Stock Performance

Shares of NASDAQ:FOLD traded up $0.07 during trading on Wednesday, hitting $9.59. The stock had a trading volume of 1,961,452 shares, compared to its average volume of 2,723,220. Amicus Therapeutics, Inc. has a 12-month low of $9.02 and a 12-month high of $14.57. The stock has a market capitalization of $2.87 billion, a price-to-earnings ratio of -28.21 and a beta of 0.68. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. The stock has a 50-day simple moving average of $10.89 and a two-hundred day simple moving average of $10.59.

Analyst Upgrades and Downgrades

A number of brokerages have commented on FOLD. Bank of America boosted their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Thursday, October 17th. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, November 7th. JPMorgan Chase & Co. upped their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the company an "overweight" rating in a research report on Tuesday, November 12th. StockNews.com upgraded shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday. Finally, Morgan Stanley decreased their price target on shares of Amicus Therapeutics from $19.00 to $18.00 and set an "overweight" rating on the stock in a research note on Friday, October 11th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $17.63.

Insider Activity

In related news, CEO Bradley L. Campbell sold 7,901 shares of the firm's stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total value of $98,762.50. Following the sale, the chief executive officer now owns 886,654 shares of the company's stock, valued at $11,083,175. This trade represents a 0.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 30,401 shares of company stock worth $352,038 over the last three months. 2.20% of the stock is currently owned by corporate insiders.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.